SEC11A: A Potential Drug Target Or Biomarker (G23478)

Target Name: SEC11A

NCBI ID: G23478

SEC11A

SEC11A: A Potential Drug Target Or Biomarker

SEC11A (Endopeptidase SP18) is a protein that is expressed in various cell types in the human body. It is a member of the endopeptidase family, which is a group of enzymes that are involved in the breakdown of peptides. This protein is of particular interest as a potential drug target or biomarker due to its unique structure and its involvement in a variety of cellular processes.

SEC11A is a 14kDa protein that is expressed in various cell types, including neurons, muscle cells, and intestinal epithelial cells. It is highly conserved, with a calculated pI of 6.9 and a predicted hydrophobicity of 0.47. This makes it a good candidate for drug targeting, as drugs that bind to this protein are likely to be able to cross-react with it in various cell types.

One of the key features of SEC11A is its catalytic active site. This site is located at the N-terminus of the protein and is responsible for the catalytic activity of the enzyme. The N-terminus of SEC11A contains a positively charged lysine residue base, which is known as an electrostatic interaction pocket (ESP). This pocket structure is thought to play a role in the stability and activity of the enzyme.

In addition to its catalytic active site, SEC11A also has a number of potential drug-binding sites. For example, the amino acid residue Asp122 is known to be a critical site for drug binding, as it is involved in the interaction between the enzyme and many small molecules. The side chain of Asp122 has a number of possible binding sites, which could make it a target for drugs that are designed to modulate the activity of SEC11A.

Another potential drug target for SEC11A is its conserved ty. As mentioned earlier, SEC11A is highly conserved and has a calculated pI of 6.9. This suggests that it is unlikely to have a large number of different conformers, which could make it difficult to predict the binding of drugs. However, this also means that the protein is likely to have a relatively limited number of potential binding sites, which could make it more accessible for drug targeting.

In conclusion, SEC11A is a protein that is of particular interest as a potential drug target or biomarker due to its unique structure and its involvement in various cellular processes. Its catalytic active site and potential drug-binding sites make it a likely candidate for drug targeting , while its high conservation could make it more accessible for drug development. Further research is needed to fully understand the potential of SEC11A as a drug target or biomarker.

Protein Name: SEC11 Homolog A, Signal Peptidase Complex Subunit

Functions: Catalytic component of the signal peptidase complex (SPC) which catalyzes the cleavage of N-terminal signal sequences from nascent proteins as they are translocated into the lumen of the endoplasmic reticulum (PubMed:34388369). Specifically cleaves N-terminal signal peptides that contain a hydrophobic alpha-helix (h-region) shorter than 18-20 amino acids (PubMed:34388369)

The "SEC11A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC11A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets